financetom
Business
financetom
/
Business
/
Suspect in killing of UnitedHealth executive to face federal charges, NYT reports
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Suspect in killing of UnitedHealth executive to face federal charges, NYT reports
Dec 18, 2024 8:27 PM

Dec 18 (Reuters) - Luigi Mangione, the suspect indicted

on murder charges in the shooting of UnitedHealthcare executive

Brian Thompson, will now face federal charges that could attract

the death penalty, the New York Times reported late on

Wednesday.

It was not immediately clear what charges the suspect would

face in the federal case but they will be in addition to the New

York state murder indictment, the report added, citing people

familiar with the matter.

Federal charges would potentially allow prosecutors to

pursue the death penalty, which has been outlawed in New York

for decades, it said.

The U.S. Department Of Justice did not immediately respond

to request for comment.

In the state case against him, Mangione, 26, has been

indicted on 11 counts, including first-degree murder and murder

as a crime of terrorism.

He would face a mandatory sentence of life in prison without

the possibility of parole if convicted on all of those counts.

Ivy League-educated Mangione was charged with murder on Dec.

9 for the killing of Thompson outside a Manhattan hotel before a

company conference, following a five-day manhunt.

The killing of Thompson has ignited an outpouring of anger

from Americans struggling to receive and pay for medical care.

Mangione suffered from chronic back pain that affected his

daily life, according to friends and social media posts, though

it is unclear whether his own health played a role in the

shooting.

(Reporting by Gursimran Kaur in Bengaluru)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BMO Tweaks Dollarama Estimate Ahead of Q1, Says Near-Term Valuation Elevated
BMO Tweaks Dollarama Estimate Ahead of Q1, Says Near-Term Valuation Elevated
Jun 3, 2024
02:00 PM EDT, 06/03/2024 (MT Newswires) -- Dollarama ( DLMAF ) reports first quarter results on June 12 before market. BMO has lowered its first quarter SSS to 6% from 7% (Street 5.6%) after considering the possibility that more normalization may have occurred than previously assumed. EPS estimate is unchanged at $0.75 (in line with Street). According to analyst Tamy...
Update: Science Applications International Shares Fall After Lower Fiscal Q1 Adjusted Earnings, Revenue; Fiscal 2025 Guidance Reiterated
Update: Science Applications International Shares Fall After Lower Fiscal Q1 Adjusted Earnings, Revenue; Fiscal 2025 Guidance Reiterated
Jun 3, 2024
02:02 PM EDT, 06/03/2024 (MT Newswires) -- (Updates with the latest stock movement in the headline and the first paragraph.) Science Applications International ( SAIC ) shares fell nearly 11% in recent Monday trading after reporting lower fiscal Q1 adjusted earnings and revenue. The company reported fiscal Q1 adjusted earnings of $1.92 per diluted share, down from $2.14 a year...
Pfizer Unusual Options Activity For June 03
Pfizer Unusual Options Activity For June 03
Jun 3, 2024
Investors with a lot of money to spend have taken a bullish stance on Pfizer ( PFE ) . And retail traders should know. We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know. But when something this big...
Optimi Health Up 12% After Reporting Drug Establishment License From Health Canada
Optimi Health Up 12% After Reporting Drug Establishment License From Health Canada
Jun 3, 2024
02:07 PM EDT, 06/03/2024 (MT Newswires) -- Optimi Health ( OPTHF ) , a licensed psychedelics pharmaceutical manufacturer specializing in controlled substances, was last seen up 12% after the company on Monday said Health Canada awarded the company a Drug Establishment Licence to manufacture and sell its MDMA and psilocybin capsules. The designation affirmed a compliant rating for Good Manufacturing...
Copyright 2023-2026 - www.financetom.com All Rights Reserved